Annalisa Piccinno
Overview
Explore the profile of Annalisa Piccinno including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
71
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rony F, Cortellini M, Guasconi A, Mathews K, Piccinno A, Poli G, et al.
Pulm Pharmacol Ther
. 2024 Apr;
85:102299.
PMID: 38663512
Introduction: Use of propellants with high global warming potential (such as HFA-134a) for pressurised metered-dose inhalers (pMDIs) is being phased down. Switching to dry-powder inhalers may not be clinically feasible...
2.
Dani C, Talosi G, Piccinno A, Ginocchio V, Balla G, Lavizzari A, et al.
J Pediatr
. 2022 Mar;
246:40-47.e5.
PMID: 35257740
Objective: To investigate the efficacy and safety of nebulized poractant alfa (at 200 and 400 mg/kg doses) delivered in combination with nasal continuous positive airway pressure compared with nasal continuous...
3.
Sweet D, Turner M, Stranak Z, Plavka R, Clarke P, Stenson B, et al.
J Matern Fetal Neonatal Med
. 2020 Dec;
35(24):4739-4742.
PMID: 33345663
Objective: To assess at 24 months corrected age (CA) the neurological, respiratory, and general health status of children born prematurely from 27 to 33 weeks' gestation who were treated in...
4.
Ramanathan R, Biniwale M, Sekar K, Hanna N, Golombek S, Bhatia J, et al.
J Pediatr
. 2020 Aug;
227:326-327.
PMID: 32818480
No abstract available.
5.
Ramanathan R, Biniwale M, Sekar K, Hanna N, Golombek S, Bhatia J, et al.
J Pediatr
. 2020 Jun;
225:90-96.e1.
PMID: 32553868
Objective: To compare efficacy and safety of a new synthetic surfactant, CHF5633, enriched with surfactant proteins, SP-B and SP-C peptide analogues, with porcine surfactant, poractant alfa, for the treatment of...
6.
Singh D, van den Berg F, Leaker B, Corradi M, Jabbal S, Collarini S, et al.
Br J Clin Pharmacol
. 2018 Dec;
85(4):729-736.
PMID: 30586199
Aims: To demonstrate the noninferiority of extrafine beclomethasone/formoterol fumarate (BDP/FF) dry powder inhaler (DPI) vs. extrafine BDP/FF pressurized metered dose inhaler (pMDI; Foster® 100/6 μg NEXThaler and pMDI, respectively) in...
7.
Sweet D, Turner M, Stranak Z, Plavka R, Clarke P, Stenson B, et al.
Arch Dis Child Fetal Neonatal Ed
. 2017 May;
102(6):F497-F503.
PMID: 28465315
Objective: CHF5633 (Chiesi Farmaceutici S.p.A., Parma, Italy) is the first fully synthetic surfactant enriched by peptide analogues of human surfactant proteins. We planned to assess safety and tolerability of CHF5633...
8.
Singh D, Ciurlia G, Piccinno A, Muraro A, Bocchi M, Scuri M
Pulm Pharmacol Ther
. 2017 Jan;
42:43-51.
PMID: 28065679
Introduction: An extrafine combination of beclometasone dipropionate (BDP) and formoterol fumarate (FF) via a pressurised metered-dose inhaler (pMDI) has been commercially available for some years for the management of asthma...
9.
Kirsten A, Watz H, Brindicci C, Piccinno A, Magnussen H
Pulm Pharmacol Ther
. 2014 Sep;
31:79-84.
PMID: 25194884
Rationale: Asthma is a chronic inflammatory airway disease of the whole bronchial tree. In this exploratory study we investigated the effects of beclomethasone/formoterol (becl/form) and budesonide/formoterol (bud/form) fixed combinations on...
10.
Chawes B, Govoni M, Piccinno A, Kreiner-Moller E, Vissing N, Mortensen L, et al.
Br J Clin Pharmacol
. 2014 May;
78(5):1169-71.
PMID: 24830339
No abstract available.